Medicinal Products

1159. Deputy Ken O'Flynn asked the Minister for Health the total number of clinics currently delivering PrEP services nationally, including both public and private providers, and whether this number has increased since 2023. [32894/26]

1160. Deputy Ken O'Flynn asked the Minister for Health whether any national standard exists for maximum acceptable waiting times for access to PrEP services; and if not, whether such a standard will be introduced. [32895/26]

1161. Deputy Ken O'Flynn asked the Minister for Health whether her Department has assessed geographic disparities in access to PrEP services; and if so, to provide details of any identified gaps. [32896/26]

1162. Deputy Ken O'Flynn asked the Minister for Health the estimated number of individuals unable to access PrEP services due to capacity constraints in the most recent year. [32897/26]

1163. Deputy Ken O'Flynn asked the Minister for Health whether any interim or bridging access arrangements exist for individuals clinically eligible for PrEP but unable to secure an appointment within the public system. [32898/26]

1164. Deputy Ken O'Flynn asked the Minister for Health whether funding allocated to expand PrEP capacity in 2025 and 2026 has been fully utilised; and if not, the reasons for any underspend. [32899/26]

1173. Deputy Colm Burke asked the Minister for Health the steps planned to protect patients' safety in light of recent figures from the HPRA that show a major spike in the volume of illegally sourced obesity medicines detained last year. [32944/26]

1174. Deputy Colm Burke asked the Minister for Health the action she intends to take to protect patients from the health risks of the rapidly increasing availability of counterfeit obesity medicines which are untested, unregulated and unlicensed. [32945/26]

1182. Deputy Mark Wall asked the Minister for Health the steps she is taking to reduce the waiting time for patients to claim refunds for medication from the HSE raised by a person in Kildare south (details supplied); and if she will make a statement on the matter. [32970/26]

1190. Deputy Pádraig O'Sullivan asked the Minister for Health the average length of time taken by the HSE Drugs Group to issue a final reimbursement decision following receipt of a National Centre for Pharmacoeconomics Health Technology Assessment in each of the past five years; whether her Department has assessed the impact of these timelines on patients with rare diseases; and if she will make a…

1191. Deputy Pádraig O'Sullivan asked the Minister for Health whether her Department has considered introducing a managed access scheme or interim reimbursement pathway for orphan and rare disease medicines that have received European Medicines Agency authorisation but are awaiting a final HSE reimbursement decision; and if she will make a statement on the matter. [33126/26]

1192. Deputy Pádraig O'Sullivan asked the Minister for Health given that European data indicates significant variability between member states in the reimbursement of orphan medicines for rare diseases, the steps her Department is taking to align Ireland's rare disease reimbursement framework with comparable EU jurisdictions; and if she will make a statement on the matter. [33127/26]

1193. Deputy Pádraig O'Sullivan asked the Minister for Health in light of the Health Products Regulatory Authority confirming that over 750,000 dosage units of falsified and illegal medicines were detained in 2025, with a thirty-fold increase in unauthorised GLP-1 type products, whether her Department has assessed the extent to which restricted access to authorised, reimbursed GLP-1 treatments thr…

1194. Deputy Pádraig O'Sullivan asked the Minister for Health the public awareness measures her Department and the HPRA are undertaking to alert the public to the serious health risks associated with sourcing prescription medicines through unauthorised online channels, particularly in respect of GLP-1 medicines marketed as drops or microneedle patches; and if she will make a statement on the matte…

1249. Deputy Mark Wall asked the Minister for Health to clarify whether AEDs are covered under the drugs payment scheme; and if she will make a statement on the matter. [33443/26]

441. Deputy Michael Fitzmaurice asked the Minister for Health when brensocatib, although approved will be made available in Ireland; and if she will make a statement on the matter. [31571/26]

445. Deputy Michael Cahill asked the Minister for Health the percentage of the HSE medicines budget that is currently spent on 'non-oncology medicines for rare diseases; and if she will make a statement on the matter. [31631/26]

453. Deputy Marie Sherlock asked the Minister for Health if she has requested the NCPP to consider a full review of relugolix with estradiol and norethisterone acetate. [31687/26]

454. Deputy Marie Sherlock asked the Minister for Health the submitted price of ryeqo (relugolix with estradiol and norethisterone acetate) at the time of the rapid review by the NCPP in 2022. [31688/26]

455. Deputy Marie Sherlock asked the Minister for Health to list the grounds upon which the NCPP rejected a full HTA examination of Ryeqo. [31689/26]

272. Deputy Jennifer Whitmore asked the Minister for Health if she will consider approving access to xolair for a person (details supplied); and if she will make a statement on the matter. [31098/26]

274. Deputy Thomas Gould asked the Minister for Health whether she will intervene to ensure that the HSE urgently prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for Frederich's ataxia which currently can be classed as having an 'unmet need' as outlined in the National Rare Disease Strategy 2025 - 2030. [31101/26]

275. Deputy Thomas Gould asked the Minister for Health her views on whether the current delay in the reimbursement of skyclarys aligns with the equitable access promised in the newly launched National Rare Disease Strategy 2025-2030. [31102/26]

999. Deputy Paul Donnelly asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the skyclarys reimbursement negotiations (details supplied); and her views on whether the current delay aligns with the equitable access promised in the newly launched National Rare Disease Strategy 2025-2030. [29564/26]

1000. Deputy Louis O'Hara asked the Minister for Health the measures being taken to improve the timeliness of access to orphan drugs in Ireland, particularly in cases such as Friedreich's ataxia, where a treatment has been approved by the EMA but is not yet reimbursed by the HSE; and if she will make a statement on the matter. [29565/26]